Eupraxia Pharmaceuticals reported earnings of -$ 0.23 per EPRX share on Nov 10, 2026, falling short of analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.26 |
| Earnings Per Share (Surprise) | -$ 0.23 (+$ 0.03) |
| Last Year's EPS | -$ 0.26 |
| EPS YoY Change |
Out of the last 33 earnings reporting periods, Eupraxia Pharmaceuticals beat analysts’ expectations 5 times and fell short of expectations 15 time(s). Eupraxia Pharmaceuticals reported earnings per share of -$ 0.23 in the last report surpassing an estimated EPS of -$ 0.26 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.26 | -$ 0.23 | -$ 0.19 | |
| Aug 11, 2026 | -$ 0.23 | -$ 0.16 | -$ 0.26 | |
| May 12, 2026 | -$ 0.22 | -$ 0.23 | -$ 0.21 | |
| Mar 12, 2026 | -$ 0.16 | -$ 0.37 | -$ 0.21 | |
| Nov 4, 2025 | -$ 0.23 | -$ 0.19 | -$ 0.17 | |
| Aug 12, 2025 | -$ 0.21 | -$ 0.26 | -$ 0.17 | |
| May 6, 2025 | -$ 0.19 | -$ 0.21 | -$ 0.21 | |
| Mar 20, 2025 | -$ 0.18 | -$ 0.21 | -$ 0.15 | |
| Nov 7, 2024 | -$ 0.13 | -$ 0.17 | -$ 0.18 | |
| Aug 7, 2024 | -$ 0.17 | -$ 0.17 | -$ 0.25 | |
| May 8, 2024 | -$ 0.17 | -$ 0.21 | -$ 0.27 | |
| Mar 21, 2024 | - | -$ 0.15 | -$ 0.36 | |
| Nov 14, 2023 | -$ 0.11 | -$ 0.18 | -$ 0.17 | |
| Sep 30, 2023 | -$ 0.11 | -$ 0.25 | -$ 0.23 | |
| Aug 11, 2023 | -$ 0.27 | -$ 0.27 | -$ 0.41 | |
| Jun 30, 2023 | -$ 0.27 | -$ 0.36 | -$ 0.22 | |
| May 18, 2023 | -$ 0.17 | -$ 0.17 | -$ 0.23 | |
| Mar 31, 2023 | -$ 0.17 | -$ 0.23 | -$ 0.31 | |
| Dec 31, 2022 | -$ 0.13 | -$ 0.41 | -$ 0.26 | |
| Sep 30, 2022 | -$ 0.31 | -$ 0.22 | -$ 0.30 |
Eupraxia Pharmaceuticals’s stock was trading at $ 7.42 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, EPRX’s price increased to $ 8.06 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.23 | $ 7.42 | $ 8.06 | |
| Aug 11, 2026 | -$ 0.16 | $ 6.66 | $ 6.48 | |
| May 12, 2026 | -$ 0.23 | $ 7.42 | $ 7.55 | |
| Mar 12, 2026 | -$ 0.37 | $ 7.69 | $ 7.36 | |
| Nov 4, 2025 | -$ 0.19 | $ 6.09 | $ 5.67 | |
| Aug 12, 2025 | -$ 0.26 | $ 5.33 | $ 5.45 | |
| May 6, 2025 | -$ 0.21 | $ 4.01 | $ 3.79 | |
| Mar 20, 2025 | -$ 0.21 | $ 4.02 | $ 3.82 | |
| Nov 7, 2024 | -$ 0.17 | $ 3.11 | $ 3.21 | |
| Aug 7, 2024 | -$ 0.17 | $ 2.50 | $ 2.52 | |
| May 8, 2024 | -$ 0.21 | $ 2.92 | $ 2.93 |
Eupraxia Pharmaceuticals released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Eupraxia Pharmaceuticals beat analysts’ expectations during the last earnings period by
